HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
40:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
lation of the AT  receptor, which is associated with cell :@0.076190:0.084931:0.485163:0.084931:0.485163:0.069149:0.076190:0.069149:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005125:0.009903:0.004747:0.005110:0.005125:0.009223:0.009827:0.005110:0.011188:0.006441:0.004856:0.005125:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.005110:0.012564:0.009223:0.003024:0.009782:0.009223:0.005125:0.003024:0.005866:0.005125:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.005125:0.012564:0.003024:0.005125:0.009223:0.005125:0.009782:0.009827:0.003024:0.003024:0.004188
2:@0.188611:0.084597:0.193469:0.084597:0.193469:0.075443:0.188611:0.075443:0.004858
proliferation, fibrosis and inflammation.:@0.076193:0.098890:0.358692:0.098890:0.358692:0.083107:0.076193:0.083107:0.010311:0.004551:0.009903:0.003024:0.003024:0.004747:0.009827:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004642:0.003681:0.003681:0.010311:0.004551:0.009903:0.005866:0.003024:0.005866:0.004642:0.010326:0.009223:0.010357:0.004642:0.003024:0.009223:0.003666:0.003666:0.010326:0.014182:0.014182:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
6:@0.358697:0.093588:0.363555:0.093588:0.363555:0.084434:0.358697:0.084434:0.004858
 However, there :@0.363556:0.098887:0.485144:0.098887:0.485144:0.083104:0.363556:0.083104:0.004642:0.010326:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004642:0.005125:0.009223:0.009827:0.004551:0.009827:0.004188
was no evidence found in a recent meta-analysis that :@0.076189:0.112845:0.485144:0.112845:0.485144:0.097063:0.076189:0.097063:0.012564:0.010326:0.005866:0.005292:0.009223:0.009903:0.005277:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.005277:0.004747:0.009903:0.009192:0.009223:0.010357:0.005277:0.003024:0.009223:0.005292:0.010326:0.005292:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.005277:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.005292:0.005125:0.009223:0.010326:0.005125:0.004188
ARBs increase the risk of MI.  This large and comprehen-:@0.076189:0.126804:0.480945:0.126798:0.480945:0.111016:0.076189:0.111021:0.011188:0.009177:0.008678:0.005866:0.004112:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004112:0.005125:0.009223:0.009827:0.004112:0.004551:0.003024:0.005866:0.007590:0.004112:0.009903:0.004747:0.004112:0.013894:0.003417:0.004188:0.004858:0.004112:0.006441:0.009223:0.003024:0.005866:0.004112:0.003024:0.010326:0.004551:0.010175:0.009827:0.004112:0.010326:0.009223:0.010357:0.004112:0.009782:0.009903:0.014182:0.010311:0.004551:0.009827:0.009223:0.009827:0.009207:0.688220
7:@0.275441:0.121500:0.280299:0.121500:0.280299:0.112346:0.275441:0.112346:0.004858
sive analysis produced evidence to debunk the hypoth-:@0.076178:0.140757:0.480960:0.140757:0.480960:0.124974:0.076178:0.124974:0.005866:0.003024:0.008376:0.009827:0.003553:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.003553:0.010311:0.004551:0.009903:0.010357:0.009192:0.009782:0.009827:0.010357:0.003538:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.003538:0.005125:0.009903:0.003538:0.010357:0.009827:0.010311:0.009192:0.009223:0.007590:0.003538:0.005125:0.009223:0.009827:0.003538:0.009223:0.008104:0.010311:0.009903:0.005125:0.009223:0.005020
esis that ARBs increase the risk of myocardial infarction. :@0.076178:0.154715:0.485118:0.154715:0.485118:0.138933:0.076178:0.138933:0.009827:0.005866:0.003024:0.005866:0.004566:0.005125:0.009223:0.010326:0.005125:0.004551:0.011188:0.009177:0.008678:0.005866:0.004566:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004566:0.005125:0.009223:0.009827:0.004551:0.004551:0.003024:0.005866:0.007590:0.004566:0.009903:0.004747:0.004551:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.004566:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188
Compared with controls, ARBs reduce the risk of stroke, :@0.076178:0.168674:0.485118:0.168674:0.485118:0.152891:0.076178:0.152891:0.012292:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004521:0.012564:0.003024:0.005125:0.009223:0.004521:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.005866:0.004188:0.004505:0.011188:0.009177:0.008678:0.005866:0.004521:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004521:0.005125:0.009223:0.009827:0.004521:0.004551:0.003024:0.005866:0.007590:0.004521:0.009903:0.004747:0.004521:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188
heart  failure, and new-onset  diabetes with a neutral :@0.076178:0.182632:0.485133:0.182632:0.485133:0.166850:0.076178:0.166850:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.003538:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.007741:0.010326:0.009223:0.010357:0.007741:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005125:0.004188:0.003538:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.007741:0.012564:0.003024:0.005125:0.009223:0.007741:0.010326:0.007741:0.009223:0.009827:0.009192:0.005125:0.004551:0.010326:0.003024:0.004188
outcome in MI.:@0.076178:0.196591:0.186215:0.196591:0.186215:0.180808:0.076178:0.180808:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004188:0.003024:0.009223:0.004188:0.013894:0.003417:0.004188
systematic reviews of ARBs that include meta-analy-:@0.090466:0.210549:0.480945:0.210549:0.480945:0.194766:0.090466:0.194766:0.007529:0.008104:0.005866:0.005125:0.009827:0.014182:0.010326:0.005125:0.003024:0.009782:0.005549:0.004551:0.009827:0.008376:0.003024:0.009827:0.012564:0.005866:0.005549:0.009903:0.004747:0.005534:0.011188:0.009177:0.008678:0.005866:0.005549:0.005125:0.009223:0.010326:0.005125:0.005534:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.005549:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005020
ses indicate that ARBs lack the cardiovascular-protec-:@0.076178:0.224508:0.480945:0.224508:0.480945:0.208725:0.076178:0.208725:0.005866:0.009827:0.005866:0.005670:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.005655:0.005125:0.009223:0.010326:0.005125:0.005670:0.011188:0.009177:0.008678:0.005866:0.005670:0.003024:0.010326:0.009782:0.007590:0.005670:0.005125:0.009223:0.009827:0.005655:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005020:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005020
tive effects of ACEIs. This is independent of the Bp-lower-:@0.076178:0.238466:0.480945:0.238466:0.480945:0.222683:0.076178:0.222683:0.005125:0.003024:0.008376:0.009827:0.003629:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.003629:0.009903:0.004747:0.003629:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.003629:0.006441:0.009223:0.003024:0.005866:0.003629:0.003024:0.005866:0.003629:0.003024:0.009223:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.003629:0.009903:0.004747:0.003629:0.005125:0.009223:0.009827:0.003629:0.008678:0.008950:0.005020:0.003024:0.009903:0.012564:0.009827:0.004551:0.005020
ing effect and that ACEIs consistently reduce mortality, :@0.076178:0.252424:0.485133:0.252424:0.485133:0.236642:0.076178:0.236642:0.003024:0.009223:0.010175:0.004642:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004642:0.010326:0.009223:0.010357:0.004657:0.005125:0.009223:0.010326:0.005125:0.004642:0.011188:0.012292:0.008104:0.003417:0.005866:0.004657:0.009782:0.009903:0.009223:0.005866:0.003024:0.005866:0.005125:0.009827:0.009223:0.005125:0.003024:0.008104:0.004657:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004642:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004188
whereas not all ARB studies demonstrate the latter. :@0.076178:0.266383:0.451448:0.266383:0.451448:0.250600:0.076178:0.250600:0.012564:0.009223:0.009827:0.004551:0.009827:0.010326:0.005866:0.004188:0.009223:0.009903:0.005125:0.004188:0.010326:0.003024:0.003024:0.004188:0.011188:0.009177:0.008678:0.004188:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.004188:0.005125:0.009223:0.009827:0.004188:0.003024:0.010326:0.005125:0.005125:0.009827:0.004551:0.004188:0.004188
The EsC 2017 guidelines recommend the use of ACEIs :@0.090466:0.280341:0.485118:0.280341:0.485118:0.264559:0.090466:0.264559:0.006441:0.009223:0.009827:0.004188:0.008104:0.007529:0.012292:0.004203:0.008376:0.008376:0.008376:0.008376:0.004218:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004203:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.004188:0.005125:0.009223:0.009827:0.004188:0.009192:0.005866:0.009827:0.004203:0.009903:0.004747:0.004203:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188
after  sT-segment  elevation  myocardial infarction  (sTE-:@0.076178:0.294300:0.480930:0.294300:0.480930:0.278517:0.076178:0.278517:0.010326:0.004747:0.005125:0.009827:0.004551:0.004188:0.002434:0.007529:0.006441:0.005020:0.005866:0.009827:0.010175:0.014182:0.009827:0.009223:0.005125:0.004188:0.002434:0.009827:0.003024:0.009827:0.008376:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.002434:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.006637:0.003024:0.009223:0.004747:0.010326:0.004551:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.002434:0.005579:0.007529:0.006441:0.008104:0.005020
MI) and only if ARBs are not tolerated in patients with :@0.076178:0.308258:0.485148:0.308258:0.485148:0.292476:0.076178:0.292476:0.013894:0.003417:0.005579:0.006108:0.010326:0.009223:0.010357:0.006108:0.009903:0.009223:0.003024:0.008104:0.006093:0.003024:0.004747:0.006108:0.011188:0.009177:0.008678:0.005866:0.006108:0.010326:0.004551:0.009827:0.006093:0.009223:0.009903:0.005125:0.006093:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.006093:0.003024:0.009223:0.006108:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006108:0.012564:0.003024:0.005125:0.009223:0.004188
low ejection fraction heart failure. Treatment with ACE :@0.076178:0.322217:0.485118:0.322217:0.485118:0.306434:0.076178:0.306434:0.003024:0.009903:0.012564:0.005534:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005534:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.005534:0.009223:0.009827:0.010326:0.004551:0.005125:0.005534:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005534:0.006441:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005518:0.012564:0.003024:0.005125:0.009223:0.005534:0.011188:0.012292:0.008104:0.004188
inhibitors  is recommended  in  patients with  systolic LV :@0.076178:0.336175:0.485118:0.336175:0.485118:0.320392:0.076178:0.320392:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.003130:0.003024:0.005866:0.007333:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.004188:0.003130:0.003024:0.009223:0.004188:0.003130:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007333:0.012564:0.003024:0.005125:0.009223:0.004188:0.003130:0.005866:0.008104:0.005866:0.005125:0.009903:0.003024:0.003024:0.009782:0.007333:0.006985:0.010614:0.004188
dysfunction or heart failure, hypertension, or diabetes, :@0.076178:0.350134:0.485103:0.350134:0.485103:0.334351:0.076178:0.334351:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.006017:0.009903:0.004551:0.006017:0.009223:0.009827:0.010326:0.004551:0.005125:0.006017:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.006017:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.006017:0.009903:0.004551:0.006017:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004188
and should be considered in all sTEMI patients. In the :@0.076178:0.364092:0.485133:0.364092:0.485133:0.348309:0.076178:0.348309:0.010326:0.009223:0.010357:0.006290:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.006290:0.010311:0.009827:0.006290:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.006290:0.003024:0.009223:0.006290:0.010326:0.003024:0.003024:0.006290:0.007529:0.006441:0.008104:0.013894:0.003417:0.006290:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.006290:0.003417:0.009223:0.006290:0.005125:0.009223:0.009827:0.004188
context of sTEMI, valsartan was found to be non-inferior :@0.076178:0.378050:0.485148:0.378050:0.485148:0.362268:0.076178:0.362268:0.009782:0.009903:0.009223:0.005125:0.009827:0.007257:0.005125:0.004188:0.009903:0.004747:0.004203:0.007529:0.006441:0.008104:0.013894:0.003417:0.004188:0.004203:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.004203:0.012564:0.010326:0.005866:0.004203:0.004747:0.009903:0.009192:0.009223:0.010357:0.004203:0.005125:0.009903:0.004203:0.010311:0.009827:0.004203:0.009223:0.009903:0.009223:0.005020:0.003024:0.009223:0.004747:0.009827:0.004551:0.003024:0.009903:0.004551:0.004188
to  captopril in the  VALsartan  In Acute  myocardial iN-:@0.076178:0.392009:0.480945:0.392009:0.480945:0.376226:0.076178:0.376226:0.005125:0.009903:0.004188:0.002328:0.009782:0.010326:0.010311:0.005125:0.009903:0.010311:0.004551:0.003024:0.003024:0.006531:0.003024:0.009223:0.006531:0.005125:0.009223:0.009827:0.004188:0.002328:0.010614:0.011188:0.006985:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.004188:0.002328:0.003417:0.009223:0.006531:0.011188:0.009782:0.009192:0.005125:0.009827:0.004188:0.002328:0.014182:0.008104:0.009903:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.006531:0.003024:0.011188:0.005020
farcTion study. :@0.076178:0.405967:0.185383:0.405967:0.185383:0.390185:0.076178:0.390185:0.004747:0.010326:0.004551:0.009782:0.006441:0.003024:0.009903:0.009223:0.004188:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.004188
Mineralocorticoid receptor antagonist (MRA) therapy :@0.090466:0.419926:0.485133:0.419926:0.485133:0.404143:0.090466:0.404143:0.013894:0.003024:0.009223:0.009827:0.004551:0.010326:0.003024:0.009903:0.009782:0.009903:0.004551:0.005125:0.003024:0.009782:0.009903:0.003024:0.010357:0.004037:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004037:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004052:0.005579:0.013894:0.009177:0.011188:0.005579:0.004052:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
is recommended in patients with LV dysfunction (LVEF :@0.076178:0.433884:0.485148:0.433884:0.485148:0.418102:0.076178:0.418102:0.003024:0.005866:0.006017:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.009827:0.010357:0.006017:0.003024:0.009223:0.006017:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006017:0.012564:0.003024:0.005125:0.009223:0.006017:0.006985:0.010614:0.006017:0.010357:0.008104:0.005866:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.006002:0.005579:0.006985:0.010614:0.008104:0.007333:0.004188
<40%) and heart failure after STEMI. Eplerenone (selec:@0.076178:0.447843:0.475911:0.447843:0.475911:0.432060:0.076178:0.432060:0.009162:0.008376:0.008376:0.011717:0.005579:0.005292:0.010326:0.009223:0.010357:0.005292:0.009223:0.009827:0.010326:0.004551:0.005125:0.005277:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005292:0.010326:0.004747:0.005125:0.009827:0.004551:0.005277:0.007529:0.006441:0.008104:0.013894:0.003417:0.004188:0.005292:0.008104:0.010311:0.003024:0.009827:0.004551:0.009827:0.009223:0.009903:0.009223:0.009827:0.005277:0.005579:0.005866:0.009827:0.003024:0.009827:0.009782
-:@0.475911:0.447843:0.480930:0.447843:0.480930:0.432060:0.475911:0.432060:0.005020
tive aldosterone receptor antagonist) reduced the mor-:@0.076178:0.461801:0.480945:0.461801:0.480945:0.446018:0.076178:0.446018:0.005125:0.003024:0.008376:0.009827:0.003508:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.009207:0.009827:0.003508:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.003492:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.005579:0.003508:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.003492:0.005125:0.009223:0.009827:0.003492:0.014182:0.009903:0.004551:0.005020
bidity and mortality in these patients.  :@0.076178:0.475760:0.354516:0.475690:0.354516:0.459908:0.076178:0.459977:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.004188:0.010326:0.009223:0.010357:0.004188:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.005866:0.009827:0.004188:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004865:0.356935
8:@0.345469:0.470391:0.350327:0.470391:0.350327:0.461238:0.345469:0.461238:0.004858
metAbOliC synDrOme  :@0.076190:0.508393:0.293483:0.508393:0.293483:0.488228:0.076190:0.488228:0.016631:0.009609:0.007761:0.013674:0.010718:0.015522:0.008131:0.005174:0.014413:0.005174:0.009609:0.011457:0.013674:0.012935:0.010718:0.015522:0.016631:0.009609:0.005156:0.005174
AnD DiAbetes mellitus:@0.076190:0.524917:0.282784:0.524917:0.282784:0.504752:0.076190:0.504752:0.013674:0.013674:0.012935:0.005174:0.012935:0.005174:0.013674:0.010718:0.009609:0.007761:0.009609:0.009609:0.005174:0.016631:0.009609:0.008131:0.008131:0.005174:0.007761:0.011826:0.009609
Impaired insulin sensitivity and hypertension are risk fac-:@0.076190:0.540648:0.480927:0.540648:0.480927:0.524865:0.076190:0.524865:0.003417:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.004264:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004264:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004279:0.010326:0.009223:0.010357:0.004264:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004264:0.010326:0.004551:0.009827:0.004264:0.004551:0.003024:0.005866:0.007590:0.004264:0.004747:0.010326:0.009782:0.005020
tors for atherosclerosis. Impaired insulin sensitivity is also a :@0.076190:0.554607:0.485115:0.554607:0.485115:0.538824:0.076190:0.538824:0.005125:0.009903:0.004551:0.005866:0.003220:0.004747:0.009903:0.004551:0.003205:0.010326:0.005125:0.009223:0.009827:0.004551:0.009903:0.005866:0.009782:0.003024:0.009827:0.004551:0.009903:0.005866:0.003024:0.005866:0.004188:0.003205:0.003417:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.003220:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.003220:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.003235:0.003024:0.005866:0.003220:0.010326:0.003024:0.005866:0.009903:0.003220:0.010326:0.004188
precursor for type II diabetes mellitus (TIIDM). The RAAs is :@0.076190:0.568565:0.485115:0.568565:0.485115:0.552782:0.076190:0.552782:0.010311:0.004551:0.009827:0.009782:0.009192:0.004551:0.005866:0.009903:0.004551:0.003508:0.004747:0.009903:0.004551:0.003508:0.005125:0.008104:0.010311:0.009827:0.003523:0.003417:0.003417:0.003523:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003523:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.003523:0.005579:0.006441:0.003417:0.003417:0.011249:0.013894:0.005579:0.004188:0.003523:0.006441:0.009223:0.009827:0.003508:0.009177:0.011188:0.011188:0.007529:0.003508:0.003024:0.005866:0.004188
pivotal in the development of both hypertension and in-:@0.076190:0.582523:0.480957:0.582523:0.480957:0.566741:0.076190:0.566741:0.010311:0.003024:0.008376:0.009903:0.005125:0.010326:0.003024:0.003462:0.003024:0.009223:0.003462:0.005125:0.009223:0.009827:0.003462:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.003462:0.009903:0.004747:0.003462:0.010311:0.009903:0.005125:0.009223:0.003462:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.003447:0.010326:0.009223:0.010357:0.003462:0.003024:0.009223:0.005020
sulin resistance. RAAs inhibitors, such as ACEIs and ARBs, :@0.076190:0.596482:0.485130:0.596482:0.485130:0.580699:0.076190:0.580699:0.005866:0.009192:0.003024:0.003024:0.009223:0.003780:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.003765:0.009177:0.011188:0.011188:0.007529:0.003765:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.003765:0.005866:0.009192:0.009782:0.009223:0.003765:0.010326:0.005866:0.003780:0.011188:0.012292:0.008104:0.003417:0.005866:0.003765:0.010326:0.009223:0.010357:0.003765:0.011188:0.009177:0.008678:0.005866:0.004188:0.004188
may therefore improve insulin sensitivity and prevent the :@0.076190:0.610440:0.485145:0.610440:0.485145:0.594658:0.076190:0.594658:0.014182:0.010326:0.008104:0.003417:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.003402:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.003417:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.003417:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.003432:0.010326:0.009223:0.010357:0.003417:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003417:0.005125:0.009223:0.009827:0.004188
sequelae of insulin resistance, TIIDM and its effects on :@0.076190:0.624399:0.485130:0.624399:0.485130:0.608616:0.076190:0.608616:0.005866:0.009827:0.010311:0.009192:0.009827:0.003024:0.010326:0.009827:0.006290:0.009903:0.004747:0.006290:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.006305:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.006290:0.006441:0.003417:0.003417:0.011249:0.013894:0.006290:0.010326:0.009223:0.010357:0.006290:0.003024:0.005125:0.005866:0.006290:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.006290:0.009903:0.009223:0.004188
the cardiovascular system. ACEIs improve insulin sensi-:@0.076190:0.638357:0.480927:0.638357:0.480927:0.622575:0.076190:0.622575:0.005125:0.009223:0.009827:0.005927:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005927:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.004188:0.005927:0.011188:0.012292:0.008104:0.003417:0.005866:0.005927:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.005927:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005942:0.005866:0.009827:0.009223:0.005866:0.003024:0.005020
tivity in patients with hypertension and insulin resistance, :@0.076190:0.652316:0.485115:0.652316:0.485115:0.636533:0.076190:0.636533:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.003810:0.003024:0.009223:0.003810:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003810:0.012564:0.003024:0.005125:0.009223:0.003810:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009207:0.005866:0.003024:0.009903:0.009223:0.003810:0.010326:0.009223:0.010357:0.003810:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.003810:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.009782:0.009827:0.004188:0.004188
including diabetes.:@0.076190:0.666274:0.216253:0.666274:0.216253:0.650491:0.076190:0.650491:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
The exact mechanisms by which insulin sensitivity itself :@0.090478:0.680233:0.485130:0.680233:0.485130:0.664450:0.090478:0.664450:0.006441:0.009223:0.009827:0.004007:0.009827:0.007257:0.010326:0.009782:0.005125:0.004022:0.014182:0.009827:0.009782:0.009223:0.010326:0.009223:0.003024:0.005866:0.014182:0.005866:0.004022:0.010311:0.008104:0.004022:0.012564:0.009223:0.003024:0.009782:0.009223:0.004022:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004022:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004037:0.003024:0.005125:0.005866:0.009827:0.003024:0.004747:0.004188
becomes impaired are not fully understood. Angioten-:@0.076190:0.694191:0.480957:0.694191:0.480957:0.678408:0.076190:0.678408:0.010311:0.009827:0.009782:0.009903:0.014182:0.009827:0.005866:0.005201:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.009827:0.010357:0.005201:0.010326:0.004551:0.009827:0.005201:0.009223:0.009903:0.005125:0.005201:0.004747:0.009192:0.003024:0.003024:0.008104:0.005216:0.009192:0.009223:0.010357:0.009827:0.004551:0.005866:0.005125:0.009903:0.009903:0.010357:0.004188:0.005186:0.011188:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009238:0.005020
sin II plays an important role, as a result of its inhibition :@0.076190:0.708149:0.485130:0.708149:0.485130:0.692367:0.076190:0.692367:0.005866:0.003024:0.009223:0.005594:0.003417:0.003417:0.005594:0.010311:0.003024:0.010326:0.008104:0.005866:0.005594:0.010326:0.009223:0.005594:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.005579:0.004551:0.009903:0.003024:0.009827:0.004188:0.005579:0.010326:0.005866:0.005594:0.010326:0.005594:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005594:0.009903:0.004747:0.005579:0.003024:0.005125:0.005866:0.005594:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.003024:0.009903:0.009223:0.004188
of adipocyte differentiation, via the AT receptor, which :@0.076190:0.722108:0.485139:0.722072:0.485139:0.706289:0.076190:0.706325:0.009903:0.004747:0.004082:0.010326:0.010357:0.003024:0.010311:0.009903:0.009782:0.008104:0.005125:0.009827:0.004082:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004067:0.008376:0.003024:0.010326:0.004097:0.005125:0.009223:0.009827:0.004082:0.011188:0.006441:0.007221:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.004067:0.012564:0.009223:0.003024:0.009782:0.009223:-0.096330
1 :@0.357775:0.721738:0.365062:0.721738:0.365062:0.712584:0.357775:0.712584:0.004858:0.002429
leads to  accumulation  of  lipids in  muscle,  liver and :@0.076184:0.736030:0.485109:0.736030:0.485109:0.720248:0.076184:0.720248:0.003024:0.009827:0.010326:0.010357:0.005866:0.008754:0.005125:0.009903:0.004188:0.004551:0.010326:0.009782:0.009782:0.009192:0.014182:0.009192:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004551:0.009903:0.004747:0.004188:0.004551:0.003024:0.003024:0.010311:0.003024:0.010357:0.005866:0.008754:0.003024:0.009223:0.004188:0.004551:0.014182:0.009192:0.005866:0.009782:0.003024:0.009827:0.004188:0.004188:0.004551:0.003024:0.003024:0.008376:0.009827:0.004551:0.008754:0.010326:0.009223:0.010357:0.004188
pancreas, with a putative reduction in insulin sensitivity. :@0.076184:0.749989:0.485109:0.749989:0.485109:0.734206:0.076184:0.734206:0.010311:0.010326:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.004188:0.004596:0.012564:0.003024:0.005125:0.009223:0.004596:0.010326:0.004596:0.010311:0.009192:0.005125:0.010326:0.005125:0.003024:0.008376:0.009827:0.004596:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004596:0.003024:0.009223:0.004596:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004611:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.004188:0.004188
Angiotensin II is also known to impair insulin intracellular :@0.076184:0.763947:0.485124:0.763947:0.485124:0.748165:0.076184:0.748165:0.011188:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004687:0.003417:0.003417:0.004702:0.003024:0.005866:0.004702:0.010326:0.003024:0.005866:0.009903:0.004702:0.007590:0.009223:0.009903:0.012564:0.009223:0.004687:0.005125:0.009903:0.004702:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.004702:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004702:0.003024:0.009223:0.005125:0.004551:0.010326:0.009782:0.009827:0.003024:0.003024:0.009192:0.003024:0.010326:0.004551:0.004188
signalling  and disrupt the pancreatic islet  structure.  It :@0.076184:0.777906:0.485124:0.777906:0.485124:0.762123:0.076184:0.762123:0.005866:0.003024:0.010175:0.009223:0.010326:0.003024:0.003024:0.003024:0.009223:0.010175:0.004188:0.002978:0.010326:0.009223:0.010357:0.007151:0.010357:0.003024:0.005866:0.004551:0.009192:0.010311:0.005125:0.007151:0.005125:0.009223:0.009827:0.007151:0.010311:0.010326:0.009223:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009782:0.007151:0.003024:0.005866:0.003024:0.009827:0.005125:0.004188:0.002978:0.005866:0.005125:0.004551:0.009192:0.009782:0.005125:0.009192:0.004551:0.009827:0.004188:0.004188:0.002948:0.003417:0.005125:0.004188
has been suggested that angiotensin II may have a del-:@0.076184:0.791864:0.480936:0.791864:0.480936:0.776081:0.076184:0.776081:0.009223:0.010326:0.005866:0.003704:0.010311:0.009827:0.009827:0.009223:0.003689:0.005866:0.009192:0.010175:0.010175:0.009827:0.005866:0.005125:0.009827:0.010357:0.003689:0.005125:0.009223:0.010326:0.005125:0.003689:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.003689:0.003417:0.003417:0.003704:0.014182:0.010326:0.008104:0.003704:0.009223:0.010326:0.008376:0.009827:0.003689:0.010326:0.003689:0.010357:0.009827:0.003024:0.005020
eterious effect on glucose metabolism by increasing re-:@0.076184:0.805822:0.480936:0.805822:0.480936:0.790040:0.076184:0.790040:0.009827:0.005125:0.009827:0.004551:0.003024:0.009903:0.009192:0.005866:0.003976:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003976:0.009903:0.009223:0.003976:0.010175:0.003024:0.009192:0.009782:0.009903:0.005866:0.009827:0.003976:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.005866:0.014182:0.003991:0.010311:0.008104:0.003991:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.003991:0.004551:0.009827:0.005020
active oxygen species and inducing inflammation, de:@0.076184:0.819781:0.475917:0.819781:0.475917:0.803998:0.076184:0.803998:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.005020:0.009903:0.007257:0.008104:0.010175:0.009827:0.009223:0.005020:0.005866:0.010311:0.009827:0.009782:0.003024:0.009827:0.005866:0.005035:0.010326:0.009223:0.010357:0.005020:0.003024:0.009223:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.005020:0.003024:0.009223:0.003666:0.003666:0.010326:0.014182:0.014182:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.005020:0.010357:0.009827
-:@0.475917:0.819781:0.480936:0.819781:0.480936:0.803998:0.475917:0.803998:0.005020
creasing blood flow in many tissue beds, and stimulating :@0.076184:0.833739:0.485139:0.833739:0.485139:0.817957:0.076184:0.817957:0.009782:0.004551:0.009827:0.010326:0.005866:0.003024:0.009223:0.010175:0.003372:0.010311:0.003024:0.009903:0.009903:0.010357:0.003372:0.003666:0.003666:0.009903:0.012564:0.003372:0.003024:0.009223:0.003372:0.014182:0.010326:0.009223:0.008104:0.003372:0.005125:0.003024:0.005866:0.005866:0.009192:0.009827:0.003372:0.010311:0.009827:0.010357:0.005866:0.004188:0.003372:0.010326:0.009223:0.010357:0.003372:0.005866:0.005125:0.003024:0.014182:0.009192:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188
the sympathetic nervous system.  :@0.076184:0.847698:0.322957:0.847673:0.322957:0.831890:0.076184:0.831915:0.005125:0.009223:0.009827:0.004188:0.005866:0.008104:0.014182:0.010311:0.010326:0.005125:0.009223:0.009827:0.005125:0.003024:0.009782:0.004188:0.009223:0.009827:0.004551:0.008376:0.009903:0.009192:0.005866:0.004188:0.005866:0.008104:0.005866:0.005125:0.009827:0.014182:0.004188:0.004853:-0.098625
9:@0.313909:0.842374:0.318767:0.842374:0.318767:0.833220:0.313909:0.833220:0.004858
ACEIs and ARBs reduce insulin sensitivity and prevent :@0.090471:0.861631:0.485139:0.861631:0.485139:0.845849:0.090471:0.845849:0.011188:0.012292:0.008104:0.003417:0.005866:0.004989:0.010326:0.009223:0.010357:0.004989:0.011188:0.009177:0.008678:0.005866:0.004989:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004989:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005004:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.005004:0.010326:0.009223:0.010357:0.004989:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004188
the onset of TIIDM.:@0.076184:0.875590:0.213843:0.875590:0.213843:0.859807:0.076184:0.859807:0.005125:0.009223:0.009827:0.005428:0.009903:0.009223:0.005866:0.009827:0.005125:0.005428:0.009903:0.004747:0.005428:0.006441:0.003417:0.003417:0.011249:0.013894:0.004188
10:@0.213834:0.870285:0.223550:0.870285:0.223550:0.861132:0.213834:0.861132:0.004858:0.004858
 ACEIs have a beneficial effect on :@0.223553:0.875584:0.485143:0.875584:0.485143:0.859802:0.223553:0.859802:0.005428:0.011188:0.012292:0.008104:0.003417:0.005866:0.005428:0.009223:0.010326:0.008376:0.009827:0.005428:0.010326:0.005428:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.005428:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005428:0.009903:0.009223:0.004188
insulin sensitivity and they prevent the development of :@0.076188:0.889543:0.485143:0.889543:0.485143:0.873760:0.076188:0.873760:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.005337:0.005866:0.009827:0.009223:0.005866:0.003024:0.005125:0.003024:0.008376:0.003024:0.005125:0.008104:0.005352:0.010326:0.009223:0.010357:0.005337:0.005125:0.009223:0.009827:0.008104:0.005337:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.005337:0.005125:0.009223:0.009827:0.005337:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.005337:0.009903:0.004747:0.004188
new-onset type II diabetes in patients with hypertension, :@0.076188:0.903501:0.485128:0.903501:0.485128:0.887718:0.076188:0.887718:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005125:0.003402:0.005125:0.008104:0.010311:0.009827:0.003417:0.003417:0.003417:0.003417:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003417:0.003024:0.009223:0.003417:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003417:0.012564:0.003024:0.005125:0.009223:0.003417:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188:0.004188
compared with conventional antihypertensive agents, :@0.076188:0.917460:0.485143:0.917460:0.485143:0.901677:0.076188:0.901677:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.005730:0.012564:0.003024:0.005125:0.009223:0.005730:0.009782:0.009903:0.009223:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.005730:0.010326:0.009223:0.005125:0.003024:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.005730:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.004188
such as diuretics and β-blockers. The beneficial effects :@0.076188:0.931418:0.485112:0.931418:0.485112:0.915635:0.076188:0.915635:0.005866:0.009192:0.009782:0.009223:0.005231:0.010326:0.005866:0.005231:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.005866:0.005246:0.010326:0.009223:0.010357:0.005231:0.009011:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.005231:0.006441:0.009223:0.009827:0.005231:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.005231:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.004188
of RAAs blockade on the incidence of new-onset dia-:@0.076188:0.945376:0.480940:0.945376:0.480940:0.929594:0.076188:0.929594:0.009903:0.004747:0.005322:0.009177:0.011188:0.011188:0.007529:0.005322:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.005322:0.009903:0.009223:0.005322:0.005125:0.009223:0.009827:0.005322:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.005322:0.009903:0.004747:0.005322:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005125:0.005322:0.010357:0.003024:0.010326:0.005020
betes is likely to be more important in high-risk patients. :@0.519040:0.084940:0.927949:0.084940:0.927949:0.069158:0.519040:0.069158:0.010311:0.009827:0.005125:0.009827:0.005866:0.004657:0.003024:0.005866:0.004657:0.003024:0.003024:0.007590:0.009827:0.003024:0.008104:0.004672:0.005125:0.009903:0.004657:0.010311:0.009827:0.004657:0.014182:0.009903:0.004551:0.009827:0.004657:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.004657:0.003024:0.009223:0.004657:0.009223:0.003024:0.010175:0.009223:0.005020:0.004551:0.003024:0.005866:0.007590:0.004657:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004188
In  a  combined  analysis of  three  trials, HOpE,  EUROpA :@0.519040:0.099141:0.927979:0.099141:0.927979:0.083359:0.519040:0.083359:0.003417:0.009223:0.004188:0.002676:0.010326:0.004188:0.002676:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004188:0.002676:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.006879:0.009903:0.004747:0.004188:0.002676:0.005125:0.009223:0.004551:0.009827:0.009827:0.004188:0.002676:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.006879:0.010326:0.013138:0.008950:0.008104:0.004188:0.004188:0.002676:0.008104:0.009903:0.009177:0.013138:0.008950:0.011188:0.004188
and PEACE, on the benefits of ACEIs in high-risk patients, :@0.519040:0.113342:0.927994:0.113342:0.927994:0.097560:0.519040:0.097560:0.010326:0.009223:0.010357:0.003644:0.008950:0.008104:0.011188:0.012292:0.008104:0.004188:0.003629:0.009903:0.009223:0.003644:0.005125:0.009223:0.009827:0.003629:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.003629:0.009903:0.004747:0.003629:0.011188:0.012292:0.008104:0.003417:0.005866:0.003644:0.003024:0.009223:0.003644:0.009223:0.003024:0.010175:0.009223:0.005020:0.004551:0.003024:0.005866:0.007590:0.003629:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004188
a risk reduction of new-onset diabetes of 0.86 (95% CI :@0.519040:0.127543:0.927979:0.127543:0.927979:0.111760:0.519040:0.111760:0.010326:0.005866:0.004551:0.003024:0.005866:0.007590:0.005866:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.005866:0.009903:0.004747:0.005866:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005110:0.005866:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005866:0.009903:0.004747:0.005866:0.008376:0.004188:0.008376:0.008376:0.005866:0.005579:0.008376:0.008376:0.011717:0.005881:0.012292:0.003417:0.004188
0.78-0.95) was reported.:@0.519040:0.141744:0.694042:0.141744:0.694042:0.125961:0.519040:0.125961:0.008376:0.004188:0.008376:0.008376:0.005020:0.008376:0.004188:0.008376:0.008376:0.005579:0.004188:0.012564:0.010326:0.005866:0.004188:0.004551:0.009827:0.010311:0.009903:0.004551:0.005125:0.009827:0.010357:0.004188
11:@0.694053:0.136454:0.703769:0.136454:0.703769:0.127300:0.694053:0.127300:0.004858:0.004858
In the AsCOT-BpLA trial, 27% of patients had co-ex-:@0.533333:0.155958:0.923797:0.155958:0.923797:0.140175:0.533333:0.140175:0.003417:0.009223:0.006667:0.005125:0.009223:0.009827:0.006667:0.011188:0.007529:0.012292:0.013138:0.006441:0.005020:0.008678:0.008950:0.006985:0.011188:0.006667:0.005125:0.004551:0.003024:0.010326:0.003024:0.004188:0.006667:0.008376:0.008376:0.011717:0.006667:0.009903:0.004747:0.006667:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006667:0.009223:0.010326:0.010357:0.006667:0.009782:0.009903:0.005020:0.009827:0.007257:0.005020
isting type II diabetes. patients were randomised to re-:@0.519045:0.170159:0.923812:0.170159:0.923812:0.154376:0.519045:0.154376:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.005382:0.005125:0.008104:0.010311:0.009827:0.005382:0.003417:0.003417:0.005382:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.005382:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005367:0.012564:0.009827:0.004551:0.009827:0.005367:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.005367:0.005125:0.009903:0.005367:0.004551:0.009827:0.005020
ceive amlodipine/perindopril or atenolol/diuretic, with :@0.519045:0.184360:0.928000:0.184360:0.928000:0.168577:0.519045:0.168577:0.009782:0.009827:0.003024:0.008376:0.009827:0.006395:0.010326:0.014182:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.006607:0.010311:0.009827:0.004551:0.003024:0.009223:0.010357:0.009903:0.010311:0.004551:0.003024:0.003024:0.006410:0.009903:0.004551:0.006395:0.010326:0.005125:0.009827:0.009223:0.009903:0.003024:0.009903:0.003024:0.006607:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.004188:0.006395:0.012564:0.003024:0.005125:0.009223:0.004188
perindopril being  added to  the  amlodipine regimen :@0.519045:0.198560:0.928000:0.198560:0.928000:0.182778:0.519045:0.182778:0.010311:0.009827:0.004551:0.003024:0.009223:0.010357:0.009903:0.010311:0.004551:0.003024:0.003024:0.008285:0.010311:0.009827:0.003024:0.009223:0.010175:0.004188:0.004082:0.010326:0.010357:0.010357:0.009827:0.010357:0.008285:0.005125:0.009903:0.004188:0.004082:0.005125:0.009223:0.009827:0.004188:0.004082:0.010326:0.014182:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.008285:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188
and  bendroflumethiazide  +  potassium  to  the  atenolol :@0.519045:0.212761:0.927985:0.212761:0.927985:0.196979:0.519045:0.196979:0.010326:0.009223:0.010357:0.004188:0.002540:0.010311:0.009827:0.009223:0.010357:0.004551:0.009903:0.003666:0.003666:0.009192:0.014167:0.009827:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.004188:0.002525:0.009162:0.004188:0.002525:0.010311:0.009903:0.005125:0.010326:0.005866:0.005866:0.003024:0.009192:0.014182:0.004188:0.002540:0.005125:0.009903:0.004188:0.002525:0.005125:0.009223:0.009827:0.004188:0.002525:0.010326:0.005125:0.009827:0.009223:0.009903:0.003024:0.009903:0.003024:0.004188
regimen  as  required  in  order  to  achieve  pre-defined :@0.519045:0.226962:0.927985:0.226962:0.927985:0.211180:0.519045:0.211180:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.003326:0.010326:0.005866:0.004188:0.003341:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.010357:0.004188:0.003326:0.003024:0.009223:0.004188:0.003326:0.009903:0.004551:0.010357:0.009812:0.004551:0.004188:0.003326:0.005125:0.009903:0.004188:0.003326:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.004188:0.003326:0.010311:0.004551:0.009827:0.005020:0.010357:0.009827:0.003681:0.003681:0.009223:0.009827:0.010357:0.004188
blood-pressure goals.  patients were followed up for a :@0.519045:0.241163:0.927985:0.241163:0.927985:0.225380:0.519045:0.225380:0.010311:0.003024:0.009903:0.009903:0.010357:0.005020:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.006592:0.010175:0.009903:0.010326:0.003024:0.005866:0.004188:0.004188:0.002404:0.008950:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006592:0.012564:0.009827:0.004551:0.009827:0.006592:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.009827:0.010357:0.006592:0.009192:0.010311:0.006592:0.004747:0.009903:0.004551:0.006592:0.010326:0.004188
median of 5.5 years. This study was stopped early be-:@0.519045:0.255364:0.923782:0.255364:0.923782:0.239581:0.519045:0.239581:0.014182:0.009827:0.010357:0.003024:0.010326:0.009223:0.006078:0.009903:0.004747:0.006078:0.008376:0.004188:0.008376:0.006078:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188:0.006078:0.006441:0.009223:0.003024:0.005866:0.006078:0.005866:0.005125:0.009192:0.010357:0.008104:0.006078:0.012564:0.010326:0.005866:0.006078:0.005866:0.005125:0.009903:0.010311:0.010311:0.009827:0.010357:0.006078:0.009827:0.010326:0.004551:0.003024:0.008104:0.006078:0.010311:0.009827:0.005020
cause of a significant 11% decrease of total mortality, a :@0.519045:0.269565:0.927955:0.269565:0.927955:0.253782:0.519045:0.253782:0.009782:0.010326:0.009192:0.005866:0.009827:0.004082:0.009903:0.004747:0.004082:0.010326:0.004082:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.004082:0.008376:0.008376:0.011717:0.004097:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.004082:0.009903:0.004747:0.004082:0.005125:0.009903:0.005125:0.010326:0.003024:0.004082:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004188:0.004082:0.010326:0.004188
24% reduction in cardiovascular death, a 16% reduction :@0.519045:0.283766:0.928000:0.283766:0.928000:0.267983:0.519045:0.267983:0.008376:0.008376:0.011717:0.003553:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003538:0.003024:0.009223:0.003553:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.003553:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.003553:0.010326:0.003553:0.008376:0.008376:0.011717:0.003553:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188
in cardiovascular events and procedures, a 23% reduc-:@0.519045:0.297967:0.923797:0.297967:0.923797:0.282184:0.519045:0.282184:0.003024:0.009223:0.004158:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004158:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004158:0.010326:0.009223:0.010357:0.004158:0.010311:0.004551:0.009903:0.009782:0.009827:0.010357:0.009192:0.004551:0.009827:0.005866:0.004188:0.004143:0.010326:0.004158:0.008376:0.008376:0.011717:0.004158:0.004551:0.009827:0.010357:0.009192:0.009782:0.005020
tion in stroke, and a 15% reduction in renal impairment in :@0.519045:0.312168:0.927985:0.312168:0.927985:0.296385:0.519045:0.296385:0.005125:0.003024:0.009903:0.009223:0.003326:0.003024:0.009223:0.003326:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.003326:0.010326:0.009223:0.010357:0.003326:0.010326:0.003326:0.008376:0.008376:0.011717:0.003341:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003326:0.003024:0.009223:0.003326:0.004551:0.009827:0.009223:0.010326:0.003024:0.003326:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.014182:0.009827:0.009223:0.005125:0.003326:0.003024:0.009223:0.004188
favour of the amlodipine/perindopril-based regimen.  :@0.519045:0.326369:0.927997:0.326421:0.927997:0.310638:0.519045:0.310586:0.004747:0.010326:0.008376:0.009903:0.009192:0.004551:0.006123:0.009903:0.004747:0.006123:0.005125:0.009223:0.009827:0.006123:0.010326:0.014182:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.006607:0.010311:0.009827:0.004551:0.003024:0.009223:0.010357:0.009903:0.010311:0.004551:0.003024:0.003024:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.006138:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.004188:0.009718:-0.021073
12:@0.914089:0.321122:0.923805:0.321122:0.923805:0.311968:0.914089:0.311968:0.004858:0.004858
Further  analysis of patients who developed diabetes :@0.519042:0.340622:0.927967:0.340622:0.927967:0.324839:0.519042:0.324839:0.007333:0.009192:0.004551:0.005125:0.009223:0.009827:0.004551:0.004188:0.003719:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003039:0.005866:0.007922:0.009903:0.004747:0.007922:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007922:0.012564:0.009223:0.009903:0.007922:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.009827:0.010357:0.007922:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
during the trial revealed that of the subgroup of patients :@0.519042:0.354823:0.927997:0.354823:0.927997:0.339040:0.519042:0.339040:0.010357:0.009192:0.004551:0.003024:0.009223:0.010175:0.003356:0.005125:0.009223:0.009827:0.003372:0.005125:0.004551:0.003024:0.010326:0.003024:0.003372:0.004551:0.009827:0.008376:0.009827:0.010326:0.003024:0.009827:0.010357:0.003372:0.005125:0.009223:0.010326:0.005125:0.003372:0.009903:0.004747:0.003372:0.005125:0.009223:0.009827:0.003356:0.005866:0.009192:0.010311:0.010175:0.004551:0.009903:0.009192:0.010311:0.003372:0.009903:0.004747:0.003356:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
who did not have diabetes at baseline, 11.4% (n=794) of :@0.519042:0.369023:0.927982:0.369023:0.927982:0.353241:0.519042:0.353241:0.012564:0.009223:0.009903:0.003462:0.010357:0.003024:0.010357:0.003462:0.009223:0.009903:0.005125:0.003462:0.009223:0.010326:0.008376:0.009827:0.003477:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003477:0.010326:0.005125:0.003462:0.010311:0.010326:0.005866:0.009827:0.003024:0.003024:0.009223:0.009827:0.004188:0.003477:0.008376:0.008376:0.004188:0.008376:0.011717:0.003477:0.005579:0.009223:0.009162:0.008376:0.008376:0.008376:0.005579:0.003477:0.009903:0.004747:0.004188
patients assigned to the atenolol/thiazide-based treat-:@0.519042:0.383224:0.923809:0.383224:0.923809:0.367442:0.519042:0.367442:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005216:0.010326:0.005866:0.005866:0.003024:0.010175:0.009223:0.009827:0.010357:0.005231:0.005125:0.009903:0.005216:0.005125:0.009223:0.009827:0.005216:0.010326:0.005125:0.009827:0.009223:0.009903:0.003024:0.009903:0.003024:0.006607:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.005216:0.005125:0.004551:0.009827:0.010326:0.005125:0.005020
ment arm and 8% (n=567) of patients assigned to am-:@0.519042:0.397425:0.923794:0.397425:0.923794:0.381643:0.519042:0.381643:0.014182:0.009827:0.009223:0.005125:0.005549:0.010326:0.004551:0.014182:0.005549:0.010326:0.009223:0.010357:0.005549:0.008376:0.011717:0.005549:0.005579:0.009223:0.009162:0.008376:0.008376:0.008376:0.005579:0.005564:0.009903:0.004747:0.005549:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005549:0.010326:0.005866:0.005866:0.003024:0.010175:0.009223:0.009827:0.010357:0.005564:0.005125:0.009903:0.005549:0.010326:0.014182:0.005020
lodipine/perindopril-based treatment, developed type :@0.519042:0.411626:0.927982:0.411626:0.927982:0.395844:0.519042:0.395844:0.003024:0.009903:0.010357:0.003024:0.010311:0.003024:0.009223:0.009827:0.006607:0.010311:0.009827:0.004551:0.003024:0.009223:0.010357:0.009903:0.010311:0.004551:0.003024:0.003024:0.005020:0.010311:0.010326:0.005866:0.009827:0.010357:0.005670:0.005125:0.004551:0.009812:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.005655:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.009827:0.010357:0.005655:0.005125:0.008104:0.010311:0.009827:0.004188
II diabetes during the five years of follow-up. :@0.519042:0.425827:0.845507:0.425827:0.845507:0.410044:0.519042:0.410044:0.003417:0.003417:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.010357:0.009192:0.004551:0.003024:0.009223:0.010175:0.004188:0.005125:0.009223:0.009827:0.004188:0.003681:0.003681:0.008376:0.009827:0.004188:0.008104:0.009827:0.010326:0.004551:0.005866:0.004188:0.009903:0.004747:0.004188:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.005020:0.009192:0.010311:0.004188:0.004188
several meta-analyses demonstrate the value of ACEI :@0.533329:0.440028:0.927997:0.440028:0.927997:0.424245:0.533329:0.424245:0.007529:0.009827:0.008376:0.009827:0.004551:0.010326:0.003024:0.003523:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.009827:0.005866:0.003523:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.003508:0.005125:0.009223:0.009827:0.003508:0.008376:0.010326:0.003024:0.009192:0.009827:0.003523:0.009903:0.004747:0.003508:0.011188:0.012292:0.008104:0.003417:0.004188
and ARB treatment, resulting in the delay or reduction in :@0.519042:0.454229:0.927997:0.454229:0.927997:0.438446:0.519042:0.438446:0.010326:0.009223:0.010357:0.003629:0.011188:0.009177:0.008678:0.003629:0.005125:0.004551:0.009827:0.010326:0.005125:0.014167:0.009827:0.009223:0.005125:0.004188:0.003613:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.003024:0.009223:0.010175:0.003613:0.003024:0.009223:0.003629:0.005125:0.009223:0.009827:0.003613:0.010357:0.009827:0.003024:0.010326:0.008104:0.003629:0.009903:0.004551:0.003613:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003613:0.003024:0.009223:0.004188
onset of TIIDM. In 10 large clinical trials, the incidence :@0.519042:0.468430:0.927986:0.468473:0.927986:0.452691:0.519042:0.452647:0.009903:0.009223:0.005866:0.009827:0.005125:0.005231:0.009903:0.004747:0.005246:0.006441:0.003417:0.003417:0.011249:0.013894:0.004188:0.012765:0.003417:0.009223:0.005246:0.008376:0.008376:0.005246:0.003024:0.010326:0.004551:0.010175:0.009827:0.005246:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.005246:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.005246:0.005125:0.009223:0.009827:0.005231:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:-0.207084
13 :@0.626724:0.463175:0.638869:0.463175:0.638869:0.454021:0.626724:0.454021:0.004858:0.004858:0.002429
of new T2DM was 9.6% in individuals taking non-RAAs :@0.519046:0.482674:0.928001:0.482674:0.928001:0.466892:0.519046:0.466892:0.009903:0.004747:0.006395:0.009223:0.009827:0.012564:0.006395:0.006441:0.008376:0.011249:0.013894:0.006395:0.012564:0.010326:0.005866:0.006395:0.008376:0.004188:0.008376:0.011717:0.006395:0.003024:0.009223:0.006395:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.005866:0.006410:0.005125:0.010326:0.007590:0.003024:0.009223:0.010175:0.006395:0.009223:0.009903:0.009223:0.005020:0.009177:0.011188:0.011188:0.007529:0.004188
blockers, i.e. thiazides, CCBs and or beta blockers, com-:@0.519046:0.496875:0.923783:0.496875:0.923783:0.481093:0.519046:0.481093:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.003508:0.003024:0.004188:0.009827:0.004188:0.003508:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005866:0.004188:0.003508:0.012292:0.012292:0.008678:0.005866:0.003523:0.010326:0.009223:0.010357:0.003508:0.009903:0.004551:0.003508:0.010311:0.009827:0.005125:0.010326:0.003508:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.003508:0.009782:0.009903:0.014182:0.005020
pared with 7.4% in those receiving ACE inhibitors or ARBs :@0.519046:0.511076:0.927971:0.511076:0.927971:0.495293:0.519046:0.495293:0.010311:0.010326:0.004551:0.009827:0.010357:0.003613:0.012564:0.003024:0.005125:0.009223:0.003613:0.008376:0.004188:0.008376:0.011717:0.003613:0.003024:0.009223:0.003629:0.005125:0.009223:0.009903:0.005866:0.009827:0.003613:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.003024:0.009223:0.010175:0.003629:0.011188:0.012292:0.008104:0.003613:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.003613:0.009903:0.004551:0.003613:0.011188:0.009177:0.008678:0.005866:0.004188
(22%  reduction,  P<.00001).  Forty-five  patients  needed :@0.519046:0.525277:0.928016:0.525277:0.928016:0.509494:0.519046:0.509494:0.005579:0.008376:0.008376:0.011717:0.004188:0.003372:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003356:0.008950:0.009162:0.004188:0.008376:0.008376:0.008376:0.008376:0.008376:0.005579:0.004188:0.004188:0.003372:0.007333:0.009903:0.004551:0.005125:0.008104:0.005020:0.003681:0.003681:0.008376:0.009827:0.004188:0.003356:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.003372:0.009223:0.009827:0.009827:0.010357:0.009827:0.010357:0.004188
to be treated for four to five years to prevent one new :@0.519046:0.539478:0.927986:0.539478:0.927986:0.523695:0.519046:0.523695:0.005125:0.009903:0.004974:0.010311:0.009827:0.004989:0.005125:0.004551:0.009827:0.010326:0.005125:0.009827:0.010357:0.004974:0.004747:0.009903:0.004551:0.004974:0.004747:0.009903:0.009192:0.004551:0.004974:0.005125:0.009903:0.004974:0.003681:0.003681:0.008376:0.009827:0.004974:0.008104:0.009827:0.010326:0.004551:0.005866:0.004989:0.005125:0.009903:0.004974:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004974:0.009903:0.009223:0.009827:0.004974:0.009223:0.009827:0.012564:0.004188
case of TIIDM. In studies with nondiabetic patients, ARB :@0.519046:0.553679:0.927986:0.553679:0.927986:0.537896:0.519046:0.537896:0.009782:0.010326:0.005866:0.009827:0.004717:0.009903:0.004747:0.004702:0.006441:0.003417:0.003417:0.011249:0.013894:0.004188:0.004702:0.003417:0.009223:0.004702:0.005866:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004717:0.012564:0.003024:0.005125:0.009223:0.004717:0.009223:0.009903:0.009223:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004717:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004702:0.011188:0.009177:0.008678:0.004188
therapy reduced the incidence of new-onset diabetes :@0.519046:0.567880:0.928001:0.567880:0.928001:0.552097:0.519046:0.552097:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004883:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004883:0.005125:0.009223:0.009827:0.004868:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.004883:0.009903:0.004747:0.004883:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005125:0.004868:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
by 17% compared  with placebo, by 27% compared :@0.519046:0.582081:0.928001:0.582081:0.928001:0.566298:0.519046:0.566298:0.010311:0.008104:0.007847:0.008376:0.008376:0.011717:0.007847:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.003644:0.012564:0.003024:0.005125:0.009223:0.007847:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188:0.007847:0.010311:0.008104:0.007847:0.008376:0.008376:0.011717:0.007847:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188
with beta blockers, and by 24% compared with calci-:@0.519046:0.596281:0.923798:0.596281:0.923798:0.580499:0.519046:0.580499:0.012564:0.003024:0.005125:0.009223:0.005912:0.010311:0.009827:0.005125:0.010326:0.005912:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.005896:0.010326:0.009223:0.010357:0.005912:0.010311:0.008104:0.005912:0.008376:0.008376:0.011717:0.005912:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.005896:0.012564:0.003024:0.005125:0.009223:0.005912:0.009782:0.010326:0.003024:0.009782:0.003024:0.005020
um-channel blockers. :@0.519046:0.610482:0.681485:0.610482:0.681485:0.594700:0.519046:0.594700:0.009192:0.014182:0.005020:0.009782:0.009223:0.010326:0.009223:0.009223:0.009827:0.003024:0.004188:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004188
It is therefore obvious that RAAs blockade using either :@0.533334:0.624683:0.928001:0.624683:0.928001:0.608901:0.533334:0.608901:0.003417:0.005125:0.003734:0.003024:0.005866:0.003734:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.003719:0.009903:0.010311:0.008376:0.003024:0.009903:0.009192:0.005866:0.003734:0.005125:0.009223:0.010326:0.005125:0.003719:0.009177:0.011188:0.011188:0.007529:0.003719:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.003734:0.009192:0.005866:0.003024:0.009223:0.010175:0.003734:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004188
an ACEI or an ARB treatment results in a protective ef-:@0.519046:0.638884:0.923844:0.638884:0.923844:0.623102:0.519046:0.623102:0.010326:0.009223:0.005246:0.011188:0.012292:0.008104:0.003417:0.005246:0.009903:0.004551:0.005231:0.010326:0.009223:0.005246:0.011188:0.009177:0.008678:0.005246:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005231:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.005246:0.003024:0.009223:0.005246:0.010326:0.005246:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.005231:0.009827:0.004747:0.005020
fect against the development of diabetes.:@0.519046:0.653085:0.831194:0.653085:0.831194:0.637302:0.519046:0.637302:0.004747:0.009827:0.009782:0.005125:0.004188:0.010326:0.010175:0.010326:0.003024:0.009223:0.005866:0.005125:0.004188:0.005125:0.009223:0.009827:0.004188:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.004188:0.009903:0.004747:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
enD-OrGAn PrOteCtiOn :@0.519047:0.686094:0.752989:0.686094:0.752989:0.665929:0.519047:0.665929:0.009609:0.013674:0.012935:0.007761:0.015522:0.010718:0.015522:0.013674:0.013674:0.005174:0.010348:0.010718:0.015522:0.007761:0.009609:0.014413:0.007761:0.005174:0.015522:0.013674:0.005174
The heart, kidney, retina and brain are the end organs :@0.519047:0.702077:0.928017:0.702077:0.928017:0.686295:0.519047:0.686295:0.006441:0.009223:0.009827:0.005110:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.005110:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.004188:0.005110:0.004551:0.009827:0.005125:0.003024:0.009223:0.010326:0.005110:0.010326:0.009223:0.010357:0.005110:0.010311:0.004551:0.010326:0.003024:0.009223:0.005110:0.010326:0.004551:0.009827:0.005110:0.005125:0.009223:0.009827:0.005110:0.009827:0.009223:0.010357:0.005110:0.009903:0.004551:0.010175:0.010326:0.009223:0.005866:0.004188
for disease development in patients with hypertension :@0.519047:0.716278:0.927987:0.716278:0.927987:0.700496:0.519047:0.700496:0.004747:0.009903:0.004551:0.005866:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005881:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.005866:0.003024:0.009223:0.005881:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005881:0.012564:0.003024:0.005125:0.009223:0.005881:0.009223:0.008104:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.004188
and/or  diabetes mellitus. Both  ACEIs and ARBs have :@0.519047:0.730479:0.928002:0.730479:0.928002:0.714697:0.519047:0.714697:0.010326:0.009223:0.010357:0.006607:0.009903:0.004551:0.004188:0.003704:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.007907:0.014182:0.009827:0.003024:0.003024:0.003024:0.005125:0.009192:0.005866:0.004188:0.007907:0.008678:0.009903:0.005125:0.009223:0.004188:0.003704:0.011188:0.012292:0.008104:0.003417:0.005866:0.007907:0.010326:0.009223:0.010357:0.007907:0.011188:0.009177:0.008678:0.005866:0.007907:0.009223:0.010326:0.008376:0.009827:0.004188
been shown to reduce the incidence of cardiovascular :@0.519047:0.744680:0.927987:0.744680:0.927987:0.728897:0.519047:0.728897:0.010311:0.009827:0.009827:0.009223:0.003991:0.005866:0.009223:0.009903:0.012564:0.009223:0.003991:0.005125:0.009903:0.003991:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.003991:0.005125:0.009223:0.009827:0.003991:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.003991:0.009903:0.004747:0.003991:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
events, micro and macro-albuminuria (a reduction  in :@0.519047:0.758881:0.928002:0.758881:0.928002:0.743098:0.519047:0.743098:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188:0.006955:0.014182:0.003024:0.009782:0.004551:0.009903:0.006955:0.010326:0.009223:0.010357:0.006955:0.014182:0.010326:0.009782:0.004551:0.009903:0.005020:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.006955:0.005579:0.010326:0.006955:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.002752:0.003024:0.009223:0.004188
the progression or development of end-stage kidney :@0.519047:0.773082:0.928017:0.773082:0.928017:0.757299:0.519047:0.757299:0.005125:0.009223:0.009827:0.007408:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.007408:0.009903:0.004551:0.007408:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.007408:0.009903:0.004747:0.007408:0.009827:0.009223:0.010357:0.005020:0.005866:0.005125:0.010326:0.010175:0.009827:0.007408:0.007590:0.003024:0.010357:0.009223:0.009827:0.008104:0.004188
disease), diabetic retinopathy and stroke. There is some :@0.519047:0.787283:0.928002:0.787283:0.928002:0.771500:0.519047:0.771500:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.005579:0.004188:0.003991:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003991:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.003976:0.010326:0.009223:0.010357:0.003991:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.003976:0.006441:0.009223:0.009827:0.004551:0.009827:0.003976:0.003024:0.005866:0.003991:0.005866:0.009903:0.014182:0.009827:0.004188
research pointing to a reduction of the incidence of de-:@0.519047:0.801484:0.923799:0.801484:0.923799:0.785701:0.519047:0.785701:0.004551:0.009827:0.005866:0.009827:0.010326:0.004551:0.009782:0.009223:0.003523:0.010311:0.009903:0.003024:0.009223:0.005125:0.003024:0.009223:0.010175:0.003523:0.005125:0.009903:0.003523:0.010326:0.003523:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.003523:0.009903:0.004747:0.003523:0.005125:0.009223:0.009827:0.003523:0.003024:0.009223:0.009782:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.003523:0.009903:0.004747:0.003523:0.010357:0.009827:0.005020
mentia. The effect on dementia has, however, not been :@0.519047:0.815685:0.927987:0.815685:0.927987:0.799902:0.519047:0.799902:0.014182:0.009827:0.009223:0.005125:0.003024:0.010326:0.004188:0.003356:0.006441:0.009223:0.009827:0.003341:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003341:0.009903:0.009223:0.003356:0.010357:0.009827:0.014182:0.009827:0.009223:0.005125:0.003024:0.010326:0.003356:0.009223:0.010326:0.005866:0.004188:0.003356:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.003341:0.009223:0.009903:0.005125:0.003341:0.010311:0.009827:0.009827:0.009223:0.004188
confirmed in large clinical trials. :@0.519047:0.829886:0.752636:0.829886:0.752636:0.814103:0.519047:0.814103:0.009782:0.009903:0.009223:0.003681:0.003681:0.004551:0.014182:0.009827:0.010357:0.004188:0.003024:0.009223:0.004188:0.003024:0.010326:0.004551:0.010175:0.009827:0.004188:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004188:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.004188
Studies  confirmed  equivalence  between  ACEIs  and :@0.533335:0.844086:0.927987:0.844086:0.927987:0.828304:0.533335:0.828304:0.007529:0.005125:0.009192:0.010357:0.003024:0.009827:0.005866:0.004188:0.002646:0.009782:0.009903:0.009223:0.003681:0.003681:0.004551:0.014167:0.009827:0.010357:0.004188:0.002646:0.009827:0.010311:0.009192:0.003024:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188:0.002646:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004188:0.002631:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.002646:0.010326:0.009223:0.010357:0.004188
ARBs with regard to  reno-protection.  Telmisartan was :@0.519047:0.858553:0.928002:0.858553:0.928002:0.842770:0.519047:0.842770:0.011188:0.009177:0.008678:0.005866:0.007499:0.012564:0.003024:0.005125:0.009223:0.007499:0.004551:0.009827:0.010175:0.010326:0.004551:0.010357:0.007499:0.005125:0.009903:0.004188:0.003296:0.004551:0.009827:0.009223:0.009903:0.005020:0.010311:0.004551:0.009888:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003296:0.006441:0.009827:0.003024:0.014182:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.007499:0.012564:0.010326:0.005866:0.004188
shown to be non-inferior to enalapril in providing long-:@0.519047:0.873019:0.923829:0.873019:0.923829:0.857237:0.519047:0.857237:0.005866:0.009223:0.009903:0.012564:0.009223:0.005428:0.005125:0.009903:0.005428:0.010311:0.009827:0.005428:0.009223:0.009903:0.009223:0.005020:0.003024:0.009223:0.004747:0.009827:0.004551:0.003024:0.009903:0.004551:0.005413:0.005125:0.009903:0.005428:0.009827:0.009223:0.010326:0.003024:0.010326:0.010311:0.004551:0.003024:0.003024:0.005443:0.003024:0.009223:0.005428:0.010311:0.004551:0.009903:0.008376:0.003024:0.010357:0.003024:0.009223:0.010175:0.005428:0.003024:0.009903:0.009223:0.010175:0.005020
term renoprotection in those with type II diabetes. This :@0.519047:0.887486:0.927987:0.887486:0.927987:0.871703:0.519047:0.871703:0.005125:0.009827:0.004551:0.014182:0.005624:0.004551:0.009827:0.009223:0.009903:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005609:0.003024:0.009223:0.005639:0.005125:0.009223:0.009903:0.005866:0.009827:0.005624:0.012564:0.003024:0.005125:0.009223:0.005639:0.005125:0.008104:0.010311:0.009827:0.005639:0.003417:0.003417:0.005639:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.005639:0.006441:0.009223:0.003024:0.005866:0.004188
finding  supports  the  clinical  equivalence  of  angioten:@0.519047:0.901952:0.918794:0.901952:0.918794:0.886170:0.519047:0.886170:0.003681:0.003681:0.009223:0.010357:0.003024:0.009223:0.010175:0.004188:0.002419:0.005866:0.009192:0.010311:0.010311:0.009903:0.004551:0.005125:0.005866:0.004188:0.002419:0.005125:0.009223:0.009827:0.004188:0.002419:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004188:0.002434:0.009827:0.010311:0.009192:0.003024:0.008376:0.010326:0.003024:0.009827:0.009223:0.009782:0.009827:0.004188:0.002419:0.009903:0.004747:0.004188:0.002419:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223
-:@0.918794:0.901952:0.923814:0.901952:0.923814:0.886170:0.918794:0.886170:0.005020
sin  II receptor  blockers and ACE inhibitors in patients :@0.519047:0.916419:0.928002:0.916419:0.928002:0.900636:0.519047:0.900636:0.005866:0.003024:0.009223:0.004188:0.003220:0.003417:0.003417:0.007408:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.003205:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.007408:0.010326:0.009223:0.010357:0.007408:0.011188:0.012292:0.008104:0.007408:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.007408:0.003024:0.009223:0.007408:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188
suffering from conditions at high risk for cardiovascular :@0.519047:0.930885:0.928002:0.930885:0.928002:0.915102:0.519047:0.915102:0.005866:0.009192:0.004747:0.004747:0.009827:0.004551:0.003024:0.009223:0.010175:0.005413:0.004747:0.004551:0.009903:0.014182:0.005413:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005866:0.005413:0.010326:0.005125:0.005413:0.009223:0.003024:0.010175:0.009223:0.005413:0.004551:0.003024:0.005866:0.007590:0.005413:0.004747:0.009903:0.004551:0.005413:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004188
events.:@0.519047:0.945352:0.571480:0.945352:0.571480:0.929569:0.519047:0.929569:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188
14 :@0.571477:0.940064:0.583622:0.940064:0.583622:0.930910:0.571477:0.930910:0.004858:0.004858:0.002429
Antihypertensive treatment to feel better:@1.072564:0.051797:1.900762:0.051797:1.900762:0.020681:1.072564:0.020681:0.033437:0.023975:0.015343:0.010555:0.023862:0.022241:0.024352:0.025898:0.017567:0.015343:0.025898:0.023975:0.019338:0.010555:0.022505:0.025898:0.011874:0.015343:0.017567:0.025898:0.021864:0.015343:0.036377:0.025898:0.023975:0.015343:0.011874:0.015343:0.025898:0.011874:0.013081:0.025898:0.025898:0.011837:0.011874:0.024352:0.025898:0.015343:0.015343:0.025898:0.017567
10/10:@1.603401:0.835327:1.703770:0.835327:1.703770:0.792624:1.603401:0.792624:0.022304:0.022304:0.011152:0.022304:0.022304
10/20:@1.603401:0.862897:1.703770:0.862897:1.703770:0.820194:1.603401:0.820194:0.022304:0.022304:0.011152:0.022304:0.022304
For full prescribing information refer to package insert approved by the medicines regulatory authority. Further information :@1.319742:0.935192:1.875129:0.935192:1.875129:0.925763:1.319742:0.925763:0.006282:0.005716:0.003424:0.002858:0.002858:0.005716:0.002282:0.002282:0.002858:0.005716:0.003424:0.005716:0.005140:0.005140:0.003424:0.002282:0.005716:0.002282:0.005716:0.005716:0.002858:0.002282:0.005716:0.002858:0.005716:0.003424:0.008564:0.005716:0.002858:0.002282:0.005716:0.005716:0.002858:0.003424:0.005716:0.002858:0.005716:0.003424:0.002858:0.002858:0.005716:0.002858:0.005716:0.005716:0.005140:0.005140:0.005716:0.005716:0.005716:0.002858:0.002282:0.005716:0.005140:0.005716:0.003424:0.002858:0.002858:0.005716:0.005716:0.005716:0.003424:0.005716:0.005140:0.005716:0.005716:0.002858:0.005716:0.005140:0.002858:0.002858:0.005716:0.005716:0.002858:0.008564:0.005716:0.005716:0.002282:0.005140:0.002282:0.005716:0.005716:0.005140:0.002858:0.003424:0.005716:0.005716:0.005716:0.002282:0.005716:0.002858:0.005716:0.003424:0.005140:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716:0.003424:0.002282:0.002858:0.005140:0.002858:0.002858:0.006282:0.005716:0.003424:0.002858:0.005716:0.005716:0.003424:0.002858:0.002282:0.005716:0.002858:0.005716:0.003424:0.008564:0.005716:0.002858:0.002282:0.005716:0.005716:0.002858
available on request to the holder of registration. Litha Pharma (Pty) Ltd. Reg. no.: 1994/008717/07. 106 16th Rd, Midrand.:@1.319742:0.946968:1.877525:0.946968:1.877525:0.937540:1.319742:0.937540:0.005716:0.005140:0.005716:0.002282:0.002282:0.005716:0.005716:0.002282:0.005716:0.002858:0.005716:0.005716:0.002858:0.003424:0.005716:0.005716:0.005716:0.005716:0.005140:0.002858:0.002858:0.002858:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716:0.002282:0.005716:0.005716:0.003424:0.002858:0.005716:0.002858:0.002858:0.003424:0.005716:0.005716:0.002282:0.005140:0.002858:0.003424:0.005716:0.002858:0.002282:0.005716:0.005716:0.002858:0.002879:0.005716:0.002282:0.002858:0.005716:0.005716:0.002858:0.006857:0.005716:0.005716:0.003424:0.008564:0.005716:0.002858:0.003424:0.006857:0.002858:0.005140:0.003424:0.002858:0.005716:0.002858:0.005716:0.002858:0.002858:0.007423:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.002858:0.002858:0.005716:0.005716:0.005716:0.005716:0.002858:0.005716:0.005716:0.005716:0.005716:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.005716:0.002858:0.007423:0.005716:0.002858:0.002858:0.008564:0.002282:0.005716:0.003424:0.005716:0.005716:0.005716:0.002858
S3 Zaneril 10/10. Each tablet contains: 10,0 mg Lercanidipine hydrochloride, 10,0 mg Enalapril maleate. Reg. no. 41/7.1/0935.:@1.319742:0.908301:1.894663:0.908301:1.894663:0.898872:1.319742:0.898872:0.006857:0.005716:0.002858:0.006282:0.005716:0.005716:0.005716:0.003424:0.002282:0.002282:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.002858:0.006857:0.005716:0.005140:0.005716:0.002858:0.002858:0.005716:0.005716:0.002282:0.005716:0.002858:0.002858:0.005140:0.005716:0.005716:0.002858:0.005716:0.002282:0.005716:0.005140:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.002858:0.008564:0.005716:0.002858:0.005716:0.005716:0.003424:0.005140:0.005716:0.005716:0.002282:0.005716:0.002282:0.005716:0.002282:0.005716:0.005716:0.002868:0.005716:0.005140:0.005716:0.003424:0.005716:0.005140:0.005716:0.002282:0.005716:0.003424:0.002282:0.005716:0.005716:0.002858:0.002868:0.005716:0.005716:0.002858:0.005716:0.002858:0.008564:0.005716:0.002858:0.006857:0.005716:0.005716:0.002282:0.005716:0.005716:0.003424:0.002282:0.002282:0.002868:0.008564:0.005716:0.002282:0.005716:0.005716:0.002858:0.005716:0.002858:0.002858:0.007423:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.002858:0.005716:0.002858:0.005716:0.005716:0.005716:0.005716:0.002858
S3 Zaneril 10/20. Each tablet contains: 10,0 mg Lercanidipine hydrochloride, 20,0 mg Enalapril maleate. Reg. no. 41/7.1/0936. :@1.319742:0.917722:1.897521:0.917722:1.897521:0.908293:1.319742:0.908293:0.006857:0.005716:0.002858:0.006282:0.005716:0.005716:0.005716:0.003424:0.002282:0.002282:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.002858:0.006857:0.005716:0.005140:0.005716:0.002858:0.002858:0.005716:0.005716:0.002282:0.005716:0.002858:0.002858:0.005140:0.005716:0.005716:0.002858:0.005716:0.002282:0.005716:0.005140:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.002858:0.008564:0.005716:0.002858:0.005716:0.005716:0.003424:0.005140:0.005716:0.005716:0.002282:0.005716:0.002282:0.005716:0.002282:0.005716:0.005716:0.002868:0.005716:0.005140:0.005716:0.003424:0.005716:0.005140:0.005716:0.002282:0.005716:0.003424:0.002282:0.005716:0.005716:0.002858:0.002868:0.005716:0.005716:0.002858:0.005716:0.002858:0.008564:0.005716:0.002858:0.006857:0.005716:0.005716:0.002282:0.005716:0.005716:0.003424:0.002282:0.002282:0.002868:0.008564:0.005716:0.002282:0.005716:0.005716:0.002858:0.005716:0.002858:0.002858:0.007423:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.002858:0.005716:0.002858:0.005716:0.005716:0.005716:0.005716:0.002858:0.002858
LP 2202 07/2019:@1.860475:0.979541:1.925733:0.979541:1.925733:0.971684:1.860475:0.971684:0.004764:0.005714:0.002382:0.004764:0.004764:0.004764:0.004764:0.002382:0.004764:0.004764:0.002382:0.004764:0.004764:0.004764:0.004764
Zaneril Advert A4 275X210mm.indd   1:@1.008365:1.032515:1.185506:1.032515:1.185506:1.023086:1.008365:1.023086:0.006282:0.005716:0.005716:0.005716:0.003424:0.002282:0.002282:0.002858:0.006857:0.005716:0.005140:0.005716:0.003424:0.002858:0.002858:0.006857:0.005716:0.002858:0.005716:0.005716:0.005716:0.006857:0.005716:0.005716:0.005716:0.008564:0.008564:0.002858:0.002282:0.005716:0.005716:0.005716:0.002858:0.002858:0.002858:0.005716
2019/07/02   18:16:@1.918701:1.032515:2.004444:1.032515:2.004444:1.023086:1.918701:1.023086:0.005716:0.005716:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716:0.002858:0.002858:0.002858:0.005716:0.005716:0.002858:0.005716:0.005716